rFIX

DRUG3 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, Bioverativ Therapeutics Inc.

Conditions

Hemophilia BSevere Hemophilia B

Phase 3

Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B

CompletedNCT00093210

Wyeth is now a wholly owned subsidiary of PfizerHemophilia B

End: 2005-09-30Updated: 2007-12-05

Study Evaluating rFIX; BeneFIX® in Hemophilia B

CompletedNCT00093171

Wyeth is now a wholly owned subsidiary of PfizerHemophilia B

End: 2005-05-31Updated: 2009-08-21

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

CompletedNCT01027364

Bioverativ Therapeutics Inc.Severe Hemophilia B

Start: 2009-12-31End: 2012-07-31Updated: 2020-12-19

Related Papers

Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B

Clinical Pharmacokinetics2025-08-014 citations

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B

Blood Advances2023-02-275 citations

Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: <i>post hoc</i> analysis of phase III trials using patient-reported outcomes

Therapeutic Advances in Hematology2023-01-013 citations

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B.

2018-11-299 citations

B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

Blood2018-11-295 citations

Clinical Outcomes in Adults/Adolescents with Hemophilia B Treated Long Term with Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis: Interim Results of the B-Yond Extension Study

Blood2016-12-021 citations

Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B-YOND Extension Study

Blood2015-12-031 citations

Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B

New England Journal of Medicine2013-12-05348 citations

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Blood2013-11-152 citations